Use of novel second-line targeted therapies in non-small cell lung cancer

Seminars in Oncology

Volumn 33, Issue SUPPL. 1, 2006, Pages 9-16

  Massarelli, Erminia ^a   Herbst, Roy S ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BEXAROTENE; CANFOSFAMIDE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; NAVELBINE; OBLIMERSEN; PACLITAXEL; PEMETREXED; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; ZD 6216;

ACNE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HUMAN; HYPERTENSION; INFECTION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; QUALITY OF LIFE; REVIEW; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 32044450314     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.12.007     Document Type: Article

References (54)

1. N. Hanna, F.A. Shepherd, F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
2. National Comprehensive Cancer Network: Practice guidelines in oncology. Available at: http://www.nccn.org/physician_gls/f_guidelines.html (accessed July 6, 2005)
3. D.G. Pfister, D.H. Johnson, C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline Update 2003 J Clin Oncol 22 2004 330 353
4. M. Fukuoka, S. Yano, G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) J Clin Oncol 21 2003 2237 2246
5. M.G. Kris, R.B. Natale, R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer A randomized trial JAMA 290 2003 2149 2158
6. E. Massarelli, F. Andre, D.D. Liu A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer Lung Cancer 39 2003 55 61
7. F.A. Shepherd, J. Dancey, R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
8. N. Thatcher, A. Chang, P. Parikh Results of a phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens Proc Am Assoc Cancer Res 2005 abstr LB-6
9. http://www.iressa-us.com/prof.asp accessed September 12, 2005
10. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
11. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung cancer Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
12. R. Sordella, D.W. Bell, D.A. Haber Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167
13. W. Pao, V. Miller, M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311
14. W. Pao, T.Y. Wang, G.J. Riely KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 57 61
15. S. Kobayashi, T.J. Boggon, T. Dayaram EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792
16. W. Pao, V.A. Miller, K.A. Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 225 235
17. F. Cappuzzo, F.R. Hirsch, E. Rossi Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 2005 643 655
18. F.A. Shepherd, J. Pereira, T.E. Ciuleanu A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group trial Proc Am Soc Clin Oncol 23 2004 18 abstr LAB7022
19. G.M. Clark, D. Zborowski, P. Santabárbara Smoking history is more predictive of survival benefit from erlotinib for patients with non-small cell lung cancer than EGFR expression Proc Am Soc Clin Oncol 23 2005 628s abstr 7033
20. R.S. Herbst, D.H. Johnson, E. Mininberg Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 2544 2555
21. R. Herbst, D. Prager, R. Hermann TRIBUTE A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
22. R. Rosell, C. Daniel, R. Ramlau Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer Proc Am Soc Clin Oncol 23 2004 618 abstr 7012
23. K. Kelly, N. Hanna, A. Rosenberg A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer Proc Am Soc Clin Oncol 22 2003 644 abstr 2592
24. F. Robert, G. Blumenschein, K. Dicke Phase Ib/IIa study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer Proc Am Soc Clin Oncol 22 2003 643 abstr 2587
25. E.S. Kim, A.M. Mauer, H.T. Tran A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer Final report Proc Am Soc Clin Oncol 22 2003 642 abstr 2581
26. R. Lilenbaum, P. Bonomi, R. Ansari A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer Final results Proc Am Soc Clin Oncol 23 2005 629s abstr 7036
27. National Institutes of Health: Information on clinical trials and human research studies. Available at: http://www.clinicaltrials.gov (accessed September 12, 2005
28. D. Hanahan, R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
29. J. Denekamp Review article angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy Br J Radiol 66 1993 181 196
30. A.W. Griffioen, G. Molema Angiogenesis potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation Pharmacol Rev 52 2000 237 268
31. N. Ferrara VEGF An update on biological and therapeutic aspects Curr Opin Biotechnol 11 2000 617 624
32. L.G. Presta, H. Chen, S.J. O'Connor Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 1997 4593 4599
33. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
34. C.G. Willett, Y. Boucher, E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147
35. D.H. Johnson, L. Fehrenbacher, W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
36. V.K. Langmuir, M.A. Cobleigh, R.S. Herbst Successful long-term therapy with bevacizumab (Avastin) in solid tumors Proc Am Soc Clin Oncol 21 2003 9a abstr 32
37. A.B. Sandler, R. Gray, J. Brahmer Randomized phase II/III Trial of paclitaxel plus carboplatin with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 Proc Am Soc Clin Oncol 23 2005 2s abstr LAB4
38. S.R. Wedge, D.J. Ogilvie, M. Dukes ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 2002 4645 4655
39. J. Dupont, D. Camastra, M.S. Gordon Phase 1 study of VEGF Trap in patients with solid tumors and lymphoma Proc Am Soc Clin Oncol 22 2003 194 abstr 776
40. H. Minami, H. Ebi, M. Tahara A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors Proc Am Soc Clin Oncol 22 2003 194 abstr 778
41. J.V. Heymach, B.E. Johnson, J.A. Rowbottom A randomized, placebo-controlled Phase II trial of ZD6474 plus docetaxel, in patients with NSCLC Proc Am Soc Clin Oncol 23 2005 197s abstr 3023
42. J. Heymach, H. West, R. Kerr ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC Results of the run-in phase of a two-part randomized phase II study Lung Cancer 49 2005 S247 abstr P-497
43. H. Rugo, R.S. Herbst, G. Liu Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors Pharmacokinetic and clinical results J Clin Oncol 23 2005 5474 5483
44. E. Raymond, S. Faivre, K. Vera Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers Proc Am Soc Clin Oncol 22 2003 192 abstr 769
45. F.A. Eskens Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 90 2004 1 7
46. S.R. Wedge, J. Kendrew, L.F. Hennequin AZD2171 A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Res 65 2005 4389 4400
47. D.C. Blakey, F.R. Westwood, M. Walker Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models Clin Cancer Res 8 2002 1974 1983
48. D.L. Crowe Receptor selective synthetic retinoids as potential cancer chemotherapy agents Curr Cancer Drug Targets 2 2002 77 86
49. H.Y. Lee, M.I. Dawson, G.L. Walsh Retinoic acid receptor- and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells Cell Growth Differ 7 1996 997 1004
50. R. Govindan, J. Crowley, L. Schwartzberg Phase II trial of bexarotene capsules in patients with non-small-cell lung cancer (NSCLC) who have failed at least 2 prior systemic therapies for stage IIIB/IV disease Proc Am Soc Clin Oncol 23 2005 649s abstr 7116
51. G.R. Blumenschein, F. Khuri, U. Gatzemeier A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer Proc Am Soc Clin Oncol 23 2005 621s abstr LBA7001
52. W.D. Henner, R.A. Figlin, L.L. Garland Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) in advanced non-small cell lung cancer Proc Am Soc Clin Oncol 21 2002 313a abstr 1249
53. V. Papadimitrakopoulou, P. Boasberg, R. Figlin Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer Proc Am Soc Clin Oncol 23 2004 648 abstr 7140
54. J.R. Graff, A.M. McNulty, K.R. Hanna The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl) suppresses signaling through the Akt pathway, induces apoptosis and suppresses growth of human colon cancer and glioblastoma xenografts MA Cancer Res 65 2005 7462 7469